IDEXX Laboratories

$446.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.35 (-0.08%) Today
$0.00 (0.00%) As of 11:01 PM UTC after-hours

Why Robinhood?

You can buy or sell IDXX and other stocks, options, and ETFs commission-free!

About IDXX

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME. The listed name for IDXX is IDEXX Laboratories, Inc. Common Stock.

CEO
Jonathan J. Mazelsky
Employees
9,200
Headquarters
Westbrook, Maine
Founded
1983
Market Cap
38.08B
Price-Earnings Ratio
80.13
Dividend Yield
Average Volume
477.72K
High Today
$454.82
Low Today
$443.14
Open Price
$449.01
Volume
338.89K
52 Week High
$485.00
52 Week Low
$168.65

Collections

IDXX Earnings

$0.00
$0.57
$1.15
$1.72
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Jan 29, Pre-Market

You May Also Like